Cefpodoxime: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "== " to "==") |
Neil.m.young (talk | contribs) (Text replacement - "5 mg" to "5mg") |
||
| Line 18: | Line 18: | ||
*Specific indication | *Specific indication | ||
**Bronchitis (chronic), acute bacterial infection: adult dosing for Infant ≥2 months to children <12 years | **Bronchitis (chronic), acute bacterial infection: adult dosing for Infant ≥2 months to children <12 years | ||
**Acute otitis media: Infant ≥2 months to children <12 years: | **Acute otitis media: Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 200 mg/dose) q 12 h for 5 days, duration according to AAP recommendation <ref>Lieberthal A. et al.The Diagnosis and Management of Acute Otitis Media.Pediatrics Mar 2013, 131 (3) e964-e999</ref>: for children < 2 years or any age with sever symptoms; 10 day-course, age 2-5 years with mild to moderate symptoms: 7 day-course; age ≥ 6 years with mild to moderate symptoms: 5 day-course | ||
**Pharyngitis/tonsillitis: | **Pharyngitis/tonsillitis: | ||
***Infant ≥2 months to children <12 years: | ***Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 100 mg/dose) q 12 h for 5-10 days | ||
***Children >12 years to adolescent: adult dosing | ***Children >12 years to adolescent: adult dosing | ||
**Acute sinusitis | **Acute sinusitis | ||
***Infant ≥2 months to children <12 years: | ***Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 200 mg/dose) q 12 h for 10 days, ISDA recommend adding Clindamycin for 10-14 days in patients with failed initial therapy or at risk of antibiotic resistance (attending daycare, age <2 years, recently hospitalised, antibiotic used with in 1 month) <ref>Chow AW et.al. ISDA clinical practice guideline for acute bacterial rhino sinusitis in children and adult.Clinical Infect Dis.2012 Apr;54(8):e72-e112</ref> | ||
***Children >12 years to adolescent: adult dosing | ***Children >12 years to adolescent: adult dosing | ||
***skin soft tissue infection and uncomplicated urinary tract infection: children >12 years to adolescent: adult dosing | ***skin soft tissue infection and uncomplicated urinary tract infection: children >12 years to adolescent: adult dosing | ||
Revision as of 07:55, 20 July 2016
General
- Type: 3rd generation cephalosporin
- Dosage Forms: tablet (100,200), suspension (50 mg/5ml, 100 mg/5ml)
- Common Trade Names: Cefopodoxine Proxetil
Adult Dosing
- Bronchitis (chronic), actue bacterial infection: 200 mg q 12 h for 10 days
- Pharyngitis/Tonsillitis: 100 mg q 12 h for 5-10 days
- Acute community acquired pneumonia: 200 mg q 12 h for 14 days
- Acute rhino sinusitis: 200 mg q 12 h for 10 days
- Skin and soft tissue infection: 400 mg q 12 h for 14 days
- Urinary tract infection, uncomplicated: 100 mg q 12 h for 7 days
Pediatric Dosing
- General range
- Infant ≥2 months to children <12 years: 10 mg/kg/day (maximum 200 mg/dose) q 12 h
- Children >12 years to adolescent: 100 to 400 mg q 12 h
- Specific indication
- Bronchitis (chronic), acute bacterial infection: adult dosing for Infant ≥2 months to children <12 years
- Acute otitis media: Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 200 mg/dose) q 12 h for 5 days, duration according to AAP recommendation [1]: for children < 2 years or any age with sever symptoms; 10 day-course, age 2-5 years with mild to moderate symptoms: 7 day-course; age ≥ 6 years with mild to moderate symptoms: 5 day-course
- Pharyngitis/tonsillitis:
- Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 100 mg/dose) q 12 h for 5-10 days
- Children >12 years to adolescent: adult dosing
- Acute sinusitis
- Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 200 mg/dose) q 12 h for 10 days, ISDA recommend adding Clindamycin for 10-14 days in patients with failed initial therapy or at risk of antibiotic resistance (attending daycare, age <2 years, recently hospitalised, antibiotic used with in 1 month) [2]
- Children >12 years to adolescent: adult dosing
- skin soft tissue infection and uncomplicated urinary tract infection: children >12 years to adolescent: adult dosing
Special Populations
- Pregnancy Rating: B
- Lactation: excreted in breast milk, not recommended for nursing women
- Renal Dosing
- Adult
- CrCl >30 mL/minute: dosage adjustment not needed
- CrCl <30 mL/minute: administer q 24 h
- Hemodialysis: 3 times/week following dialysis
- Pediatric: not defined
- Adult
- Hepatic Dosing: dosage adjustment not nescessary
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious (<1%)
- Anaphylaxis
- Hypotension
- Nephritis
- Pseudomembranous colitis
Common
- Diaper rash
- Diarrhoea
- Nausea/vomiting
- Abdominal pain
Pharmacology
- Half-life: 2-3 h, prolonged to ~10 h if CrCl <30 mL/minute
- Metabolism: De-esterified in GI tract to active metabolite
- Excretion: Urine
- Mechanism of Action: Inhibit bacterial cell walls synthesis (binding to penicillin-binding proteins (PBPs)
